CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Masimo, LidCOWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)


Name (Synonyms) Correlation

Correlated MeSH Terms (0)


Name (Synonyms) Correlation

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Effects of Cardiovascular and Pulmonary Optimisation on Cerebral Oxygenation in COVID-19 Patients With Severe ARDS

The aim of the present study is to examine whether cerebral oxygenation could be a more useful parameter than peripheral oxygen saturation to guide clinical titration of permissive hypoxemia in COVID-19 ARDS patients

NCT04392089 COVID-19 Respiratory Failure Device: Masimo, LidCO
MeSH:Respiratory Insufficiency

Primary Outcomes

Description: Cardiovascular and pulmonary optimization: Step 0 = Baseline, Step 1 = Derecruitment, Step 2 = Recruitment, Step 3 = Norepinephrine challenge, Step 4 = FiO2 increase, Step 5 = FiO2 decrease, Step 6 = Baseline 2

Measure: Changes in cerebral oxygenation (ScO2) during cardiovascular and pulmonary optimization

Time: 1 hour

Secondary Outcomes

Description: Cardiovascular and pulmonary optimization as described above

Measure: Changes in peripheral oxygen saturation (SatO2) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Changes in systolic arterial pressure (SAP) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Changes in diastolic arterial pressure (DAP) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Changes in mean arterial pressure (MAP) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Changes in heart rate (HR) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Changes in stroke volume (SV) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Changes in cardiac output (CO) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Changes in systemic vascular resistance (SVR) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Changes in peripheral perfussion index (PPI) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Changes in pH during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Changes in PaO2 during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Changes in PaCO2 during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Changes in arterial saturation (SaO2) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Changes in PvO2 during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Changes in PvCO2 during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Changes in mixed venous saturation (SvO2) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Changes in lacatate during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Changes in hemoglobine concentration (Hb) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Changes in muscular oxygenation (SmO2) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Association between cerebral oxygenation (ScO2) and peripheral oxygen saturation (SatO2) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Association between cerebral oxygenation (ScO2) and systemic arterial pressure (SAP) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Association between cerebral oxygenation (ScO2) and diastolic arterial pressure (DAP) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Association between cerebral oxygenation (ScO2) and mean arterial pressure (MAP) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Association between cerebral oxygenation (ScO2) and stroke volume (SV) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Association between cerebral oxygenation (ScO2) and heart rate (HR) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Association between cerebral oxygenation (ScO2) and cardiac output (CO) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Association between cerebral oxygenation (ScO2) and systemic vascular resistance (SVR) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Association between cerebral oxygenation (ScO2) and peripheral perfussion index (PPI) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Association between cerebral oxygenation (ScO2) and pH during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Association between cerebral oxygenation (ScO2) and PaO2 during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Association between cerebral oxygenation (ScO2) and PaCO2 during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Association between cerebral oxygenation (ScO2) and arterial saturation (SaO2) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Association between cerebral oxygenation (ScO2) and PvO2 during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Association between cerebral oxygenation (ScO2) and PvCO2 during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Association between cerebral oxygenation (ScO2) and mixed venous saturation (SvO2) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Association between cerebral oxygenation (ScO2) and lactate during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Association between cerebral oxygenation (ScO2) and hemoglobine concentration (Hb) during cardiovascular and pulmonary optimization

Time: 1 hour

Description: Cardiovascular and pulmonary optimization as described above

Measure: Association between cerebral oxygenation (ScO2) and muscular oxygenation (SmO2) during cardiovascular and pulmonary optimization

Time: 1 hour


No related HPO nodes (Using clinical trials)